SAQUINAVIR

a protease inhibitor drug, the first in its class to be FDA-approved for the treatment of HIV disease. Current practice favors the use of saquinavir in combination therapy (e.g., with nucleoside analog drugs) to avoid the development of drug-resistant virus.